Supplier log in
Future Procurement Opportunity - Supply of Lenalidomide and Pomalidomide
Details
|
Tender Closed
|
|
| RFx ID : | 27275509 |
| Tender Name : | Future Procurement Opportunity - Supply of Lenalidomide and Pomalidomide |
| Reference # : | |
| Open Date : | Q2 2023 |
| Indicative RFx Release Date : | Q3 2023 [?] |
| Tender Type : | Future Procurement Opportunity (FPO) |
| Project Status : | Initial development [?] |
| Expected number of contracts offered : | 2 |
| Tender Coverage : | Sole Agency [?] |
| Categories : |
|
| Regions: |
|
| Required Pre-qualifications : | None |
| Contact : |
Pharmac Procurement Team. procurement@Pharmac.govt.nz . |
| Agency Address : | |
| Related Tenders: | |
Pharmac is planning to issue a competitive process for the supply of lenalidomide and pomalidomide.
This competitive process may result in one or more of the following funding scenarios:
- Lenalidomide funded with current eligibility criteria;
- Lenalidomide widened access (previously untreated multiple myeloma);
- Pomalidomide for relapsed/refractory multiple myeloma
The gross expenditure on funded lenalidomide for the financial year ending 30 June 2023 is forecast to be $42,968,368 across 176,000 capsules (ex-manufacturer, excluding GST). A confidential rebate currently applies to lenalidomide, which reduces the net expenditure paid by Pharmac.
The number of funded lenalidomide capsules for the financial year ending 30 June 2024 is forecast to increase to 193,000 (12.3% 5mg, 55% 10mg, 20.3%15mg, 12.4% 25mg).
The currently eligibility criteria for lenalidomide can be found here, https://schedule.pharmac.govt.nz/ScheduleOnline.php?edition=&osq=Lenalidomide
We estimate that in 2024, over 400 people will be diagnosed with multiple myeloma, and that approximately 250 people may require treatment upon relapse of their multiple myeloma.
Funding applications for lenalidomide and pomalidomide currently under consideration can be found on the Pharmac application tracker. Links to specific funding proposals under consideration are provided below.
Lenalidomide widened access (previously untreated multiple myeloma)
• Proposal: P-001248
• Proposal: P-000072
• Proposal: P-001830
• Proposal: P-000015
Pomalidomide for relapsed or refractory multiple myeloma
• Proposal: P-001651
• Proposal: P-001699
• Proposal: P-001701
• Proposal: P-001088
Search these proposals on our application tracker, https://connect.pharmac.govt.nz/apptracker/s/.
This tender has been completed.
Date RFx was completed/updated:
Tuesday, 29 August 2023 3:08 PM (Pacific/Auckland UTC+12:00)
